Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.66	$3.54	$2.45 ▼ $4.14	$290.45M	0.25	355,697 shs	291,867 shs
NGNE Neurogene	$19.98 -0.1%	$20.30	$6.88 ▼ $74.49	$285.30M	1.69	120,149 shs	82,355 shs
VNRX VolitionRx	$0.69 -0.3%	$0.71	$0.40 ▼ $0.94	$73.77M	1.26	196,283 shs	204,557 shs
VOR Vor Biopharma	$2.06 -5.1%	$1.81	$0.13 ▼ $3.29	$260.97M	2.06	7.89 million shs	8.22 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	+3.68%	-6.15%	+24.07%	-6.15%
NGNE Neurogene	-0.05%	-2.30%	-12.06%	+16.91%	-42.82%
VNRX VolitionRx	-0.35%	+0.37%	-8.59%	+41.51%	+14.46%
VOR Vor Biopharma	-5.07%	+0.98%	-6.36%	+1,087.32%	+115.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	1.676 of 5 stars	3.3	0.6	2.5	1.3
NGNE Neurogene	2.1642 of 5 stars	3.4	3.5	0.8	1.3
VNRX VolitionRx	2.0771 of 5 stars	3.5	2.1	2.5	0.0
VOR Vor Biopharma	1.9095 of 5 stars	3.3	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	63.93% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	131.06% Upside
VNRX VolitionRx	3.00	Buy	$3.50	410.50% Upside
VOR Vor Biopharma	2.56	Moderate Buy	$6.07	194.50% Upside

Current Analyst Ratings Breakdown

Latest VNRX, NGNE, VOR, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/14/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$5.20 per share	N/A
NGNE Neurogene	$930K	306.57	N/A	N/A	$20.89 per share	0.96
VNRX VolitionRx	$1.32M	55.92	N/A	N/A	($0.11) per share	-6.23
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.61	N/A	N/A	N/A	N/A	-32.55%	-30.47%	11/6/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.31	N/A	N/A	N/A	N/A	-33.33%	-30.34%	N/A
VNRX VolitionRx	-$35.32M	-$0.25	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A
VOR Vor Biopharma	N/A	-$13.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VNRX, NGNE, VOR, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	NGNE Neurogene	-$1.15	-$1.05	+$0.10	-$1.05	N/A	N/A
8/7/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.46	-$0.44	+$0.02	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.17	19.17
NGNE Neurogene	N/A	18.07	18.07
VNRX VolitionRx	N/A	0.22	0.22
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
NGNE Neurogene	52.37%
VNRX VolitionRx	8.09%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
NGNE Neurogene	9.92%
VNRX VolitionRx	10.40%
VOR Vor Biopharma	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	79.36 million	64.99 million	Optionable
NGNE Neurogene	90	14.27 million	12.86 million	Optionable
VNRX VolitionRx	80	107.60 million	80.80 million	Optionable
VOR Vor Biopharma	140	126.68 million	65.45 million	Not Optionable

VNRX, NGNE, VOR, and AVIR Headlines

Recent News About These Companies

Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 19, 2025 | finanznachrichten.de

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

August 19, 2025 | marketbeat.com

Vor Biopharma Q3 EPS Forecast Decreased by HC Wainwright

August 19, 2025 | americanbankingnews.com

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025 | globenewswire.com

Analysts Set Expectations for Vor Biopharma FY2028 Earnings

August 17, 2025 | marketbeat.com

Wedbush Brokers Boost Earnings Estimates for Vor Biopharma

August 17, 2025 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Vor Biopharma

August 17, 2025 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Given "Buy" Rating at HC Wainwright

August 17, 2025 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC Wainwright

August 16, 2025 | marketbeat.com

Wedbush Comments on Vor Biopharma's Q3 Earnings (NYSE:VOR)

August 16, 2025 | americanbankingnews.com

Vor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder Treatment

August 13, 2025 | marketwatch.com

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

August 13, 2025 | finance.yahoo.com

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

August 13, 2025 | benzinga.com

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

August 13, 2025 | globenewswire.com

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

August 4, 2025 | globenewswire.com

Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

July 30, 2025 | marketbeat.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30, 2025 | marketbeat.com

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

July 29, 2025 | insidermonkey.com

Vor Biopharma Announces Key Leadership Changes

July 25, 2025 | theglobeandmail.com

Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop

July 23, 2025 | finance.yahoo.com

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

July 21, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VNRX, NGNE, VOR, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.66 0.00 (0.00%)

Closing price 08/25/2025 04:00 PM Eastern

Extended Trading

$3.68 +0.02 (+0.68%)

As of 08/25/2025 07:41 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Neurogene NASDAQ:NGNE

$19.98 -0.01 (-0.05%)

Closing price 08/25/2025 04:00 PM Eastern

Extended Trading

$19.92 -0.05 (-0.28%)

As of 08/25/2025 04:10 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

VolitionRx NYSE:VNRX

$0.69 0.00 (-0.35%)

Closing price 08/25/2025 03:59 PM Eastern

Extended Trading

$0.69 +0.01 (+0.79%)

As of 08/25/2025 07:51 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Vor Biopharma NYSE:VOR

$2.06 -0.11 (-5.07%)

Closing price 08/25/2025 04:00 PM Eastern

Extended Trading

$2.15 +0.09 (+4.37%)

As of 08/25/2025 07:59 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time